Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus (HSV). This article discusses an overview of HSV, diagnosis and workup, as well as treatment options for management of genital herpes.
Recent Approval of Xerese in Canada: 5% Acyclovir and 1% Hydrocortisone Topical Cream in the Treatment of Herpes Labialis
Herpes labialis is a frequently occurring viral infection of the lips and oral mucosa. Clinical data on the efficacy of topical combination acyclovir-hydrocortisone (Xerese™) product in treating herpes labialis are discussed.
Over all, acyclovir is a safe and effective drug with rare side effects when used as short term treatment. There are some concerns about side effects when acyclovir is used as long term suppressive therapy in patients, particularly pertaining to the kidneys and the blood system.
For the treatment of labial herpes, a single 1,500mg dose of famciclovir shortened the lesion healing time, shortened the time to normal skin, and resulted in faster resolution of pain and tenderness.
The Herpesviridae family (Types 1-8) continues to inflict considerable morbidity and social stigma upon humanity. Once infected with the herpes viruses, especially Types 1-3, they establish permanent residence within our nervous system and reactivate during periods of stress, trauma, and/or other precipitating factors.
Penciclovir cream (Vectavir™/Denavir™, SmithKline Beecham) is a novel product, approved in 15 countries including the USA and UK, for the treatment of herpes simplex labialis in immunocompetent adults.
Shingrix®, a new recombinant subunit vaccine, has shown a great deal of promise in the prevention of HZ in adults over the age of 50. The combination of zoster viral glycoprotein E and the AS01B adjuvant system make it a safe, efficacious option for the elderly as well as immunosuppressed individuals.